✦ LIBER ✦

37 Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer (AOC): long-term efficacy results

✍ Scribed by G. Aravantinos; G. Fountzlias; P. Kosmidis; Ma. Dimopoulos; Gp. Stathopoulos; N. Pavildis; D. Bafaloukos; S. Rigatos; S. Karpathios; Dv. Skarlos

Book ID: 118620213
Publisher: Elsevier Science
Year: 2003
Tongue: English
Weight: 168 KB
Volume: 1
Category: Article
ISSN: 1359-6349
DOI: 10.1016/s1359-6349(03)90071-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Long-term results of dose-dense paclitax

Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial

✍ Katsumata, Noriyuki; Yasuda, Makoto; Isonishi, Seiji; Takahashi, Fumiaki; Michim 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 326 KB

Randomized phase 3 trial of interferon g

Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of progression-free survival

✍ David S. Alberts; Christian Marth; Ronald D. Alvarez; Gary Johnson; Mariusz Bidz 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 233 KB

9164 An indirect comparison of the effic

9164 An indirect comparison of the efficacy of bevacizumab plus cisplatin and gemcitabine (BCG) or bevacizumab plus carboplatin and paclitaxel (BCP) versus pemetrexed plus cisplatin (PC) and cetuximab plus vinorelbine and cisplatin (CVC) in patients (pts) with advanced or recurrent non-small cell cancer (NSCLC)

✍ Walzer, S.; de Castro Carpeno, J.; Vergnenegre, A.V.; Chouaid, C.; Heigener, D.F 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 48 KB

PCN14 AN INDIRECT COMPARISON OF THE EFFI

PCN14 AN INDIRECT COMPARISON OF THE EFFICACY OF BEVACIZUMAB PLUS CISPLATIN AND GEMCITABINE (BCG) OR BEVACIZUMAB PLUS CARBOPLATIN AND PACLITAXEL (BCP) VERSUS CETUXIMAB PLUS VINORELBINE AND CISPLATIN (CVC) IN PATIENTS WITH ADVANCED OR RECURRENT NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)

✍ S Walzer; J de Castro Carpeño; A Vergnenegre; C Chouaid; D Heigener; HG Bischoff 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

A combination of a fixed dose of carbopl

A combination of a fixed dose of carboplatin plus paclitaxel and adriamycin in first line therapy for advanced ovarian cancer and suboptimal surgical cytoreduction. A phase I trial of the Spanish group for ovarian cancer research and treatment (GEICO)

✍ A. Cervantes; A. Poveda; A. González; B. Massuti; C. Balañá; A. Insa 📂 Article 📅 1999 🏛 Elsevier Science 🌐 English ⚖ 169 KB